Related Experiment Video
Updated: Feb 23, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
Published on: October 23, 2020
Competing risks modeling of cumulative effects of time-varying drug exposures
Coraline Danieli1, Michal Abrahamowicz1
1Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada.
Abstract:
An accurate assessment of drug safety or effectiveness in pharmaco-epidemiology requires defining an etiologically correct time-varying exposure model, which specifies how previous drug use affects the hazard of the event of interest. An additional challenge is to account for the multitude of mutually exclusive events that may be associated with the use of a given drug. To simultaneously address both challenges, we develop, and validate in simulations, a new approach that combines flexible modeling of the cumulative effects of time-varying exposures with competing risks methodology to separate the effects of the same drug exposure on different outcomes. To account for the dosage, duration and timing of past exposures, we rely on a spline-based weighted cumulative exposure modeling. We also propose likelihood ratio tests to test if the cumulative effects of past exposure on the hazards of the competing events are the same or different. Simulation results indicate that the estimated event-specific weight functions are reasonably accurate, and that the proposed tests have acceptable type I error rate and power. In real-life application, the proposed method indicated that recent use of antihypertensive drugs may reduce the risk of stroke but has no effect on the hazard of coronary heart disease events.
Related Concept Videos
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Pharmacodynamic Models: Emax Drug–Concentration Effect Model
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

